Achieve Life Sciences (ACHV) Accounts Payables (2010 - 2026)
Achieve Life Sciences' (ACHV) quarterly Accounts Payables came in at $806000.0 in Q1 2026, down 51.33% YoY from $1.7 million in Q1 2025, and up 9975.0% on a QoQ basis from $8000.0 in Q4 2025.
Achieve Life Sciences (ACHV) Accounts Payables (2010 - 2026) Analysis & Trends
Achieve Life Sciences (ACHV) has 17 years of Accounts Payables data on file, last reported at $806000.0 in Q1 2026.
- Quarterly Accounts Payables fell 51.33% year-over-year to $806000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $806000.0 (down 51.33% YoY) and the FY2025 annual result came in at $8000.0, down 99.59% from the prior year.
- Accounts Payables advanced to $806000.0 in Q1 2026, from $8000.0 in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $2.0 million in Q4 2024 to a low of $8000.0 in Q4 2025.
- A 5-year average of $902411.8 and a median of $656000.0 in 2022 frame the typical range for Accounts Payables.
- The widest YoY moves for Accounts Payables: up 343.97% in 2025, down 99.59% in 2025.
- Tracing ACHV's Accounts Payables over 5 years: stood at $1.7 million in 2022, then slumped by 62.77% to $618000.0 in 2023, then surged by 215.53% to $2.0 million in 2024, then slumped by 99.59% to $8000.0 in 2025, then surged by 9975.0% to $806000.0 in 2026.
- The last three Accounts Payables figures came in at $806000.0 (Q1 2026), $8000.0 (Q4 2025), and $1.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Achieve Life Sciences | 330.88 Mn | 330.88 Mn | - | 606,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 606,000.00 |
| Mar 31, 2026 | 806,000.00 |
| Dec 31, 2025 | 8,000.00 |
| Sep 30, 2025 | 1.94 Mn |
| Jun 30, 2025 | 1.22 Mn |
| Mar 31, 2025 | 1.66 Mn |
| Dec 31, 2024 | 1.95 Mn |
| Sep 30, 2024 | 1.01 Mn |
| Jun 30, 2024 | 550,000.00 |
| Mar 31, 2024 | 373,000.00 |
| Dec 31, 2023 | 618,000.00 |
| Sep 30, 2023 | 638,000.00 |
| Jun 30, 2023 | 361,000.00 |
| Mar 31, 2023 | 1.06 Mn |
| Dec 31, 2022 | 1.66 Mn |
| Sep 30, 2022 | 412,000.00 |
| Jun 30, 2022 | 656,000.00 |
| Mar 31, 2022 | 418,000.00 |
| Dec 31, 2021 | 841,000.00 |
| Sep 30, 2021 | 815,000.00 |